Second quarter earnings season is in full swing, and the results have been largely positive so far, with more positive ...

Amgen Inc (NASDAQ:AMGN) shares were slightly lower in premarket trading despite posting better-than-expected quarterly profit ...

Analysts expect Gilead Sciences to report an earnings per share (EPS) of $1.95. Investors in Gilead Sciences are eagerly ...

Amgen Inc (NASDAQ:AMGN) saw a modest decline in premarket trading even after reporting quarterly profit and revenue results ...

Detailed price information for Teva Pharmaceutical Industries ADR (TEVA-N) from The Globe and Mail including charting and trades.

Non-GAAP earnings per share for Q2 2025 beat estimates by 14.0%, rising to $6.02 (non-GAAP) and up 21% year over year (non-GAAP). Revenue increased 9% to $9.2 billion, exceeding analyst expectations ...

Biotech company Amgen (NASDAQ:AMGN) reported Q2 CY2025 results exceeding the market’s revenue expectations, with sales up 9.4 ...

The Santa Clara, Calif., chip maker logged an increase in profit and sales for its latest quarter on record server and personal computer processor sales. Fifteen of the biotechnology company's ...

The stock slipped 3.5% postmarket after the chip maker reported adjusted earnings per share in line with estimates.

Amgen on Tuesday posted quarterly financial results that beat Wall Street expectations as a 9% increase in product sales ...

Amgen (NASDAQ:AMGN) surpasses Q2 earnings and revenue expectations with a 9.4% revenue growth. Read more here.

Amgen reported higher profit and revenue in the second quarter after 15 of the biotechnology company's products saw at least double-digit sales growth. The Thousand Oaks, Calif.-based biotechnology ...